Cue Biopharma, Inc.(CUE)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

CUE iron condor setups CUE expected move CUE IV rank history CUE Fibonacci levels CUE insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CUE $31.70 —
Snapshot
$31.70
52-Week Range
$4.97 – $45.50
YTD
+213.18%
IV Rank (30D)
71.18
Straddle Price
$4.15
P/C Vol Ratio
0.47
Market Cap
$0.2B
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.87
Cost of Equity (CAPM)15.27% (VRP-adj)
WACC15.04%
Volatility Risk Premium+1040.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-7104.2%
Book / Price18.1%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-153.3%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$29.33 (Market Anchor value)
SMA 20 / Bollinger Mid$30.21
Bollinger Width / SMA20139.6% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $29.33 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-09-25 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.2B

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +6.89% 9
Feb -5.70% 9
Mar -6.56% 9
Apr +19.05% 9
May -3.60% 9
Jun -6.14% 9
Jul -9.16% 9
Aug -2.68% 9
Sep -1.57% 9
Oct +7.07% 8
Nov +6.48% 8
Dec -8.10% 8
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $30.39
SMA 50: $29.41
SMA 200: $19.82
Current: $31.70
EMA 12: $31.63
EMA 26: $30.50
MACD: 1.1330 | Signal: 0.0818
BULLISH
ADX (14): 15.79
RANGE
+DI: 22.76
−DI: 19.71

Momentum Oscillators

RSI (14): 52.43
NEUTRAL
Stoch %K: 46.82
Stoch %D: 42.94
Williams %R: -55.37

Volume & Volatility

BB Upper: $36.72
BB Lower: $24.06
NEUTRAL
OBV: 32,972,930
Vol SMA 20: 419,923
Vol ROC: 49.37%
ATR: $4.49
True Range: $2.65
HV 20: 138.6%
HV 30: 144.0%
HV 60: 126.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report: Cue Biopharma (CUE)

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 7/10)

Key Drivers:

  • Positive news sentiment around company's advancements in immunotherapies and collaborations
  • Strong momentum signals from technical indicators, such as the MACD and RSI

Primary Risks:

  • High volatility, reflected in beta and stock price movements
  • Potential for earnings misses or regulatory issues impacting stock performance

Investment Thesis: Cue Biopharma (CUE) is a biotech company focused on developing novel immunotherapies for various diseases. The recent news headlines highlighting the company's advancements in this space are likely to drive short-term growth. However, investors should be cautious of the high volatility and potential risks associated with the biotech industry.

Recent News Sentiment Impact: The positive sentiment from recent news headlines has contributed to the bullish momentum, with most articles reporting on Cue Biopharma's progress in developing novel immunotherapies.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Uptrend
  • Medium-term (1-3 months): Range-bound
  • Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • Resistance: $34.86 (upper Bollinger Band), $31.54 (SMA 50)
  • Support: $29.68 (SMA 20), $24.50 (lower Bollinger Band)

Momentum Signals:

  • RSI: Neutral (55.56) with no clear buy or sell signal
  • MACD: Bearish, but with a weak signal line crossover suggesting a potential turn higher
  • Bollinger Bands: Neutral, with the price touching the middle band

Volume Analysis:

  • Volume trends: Increasing volume on recent price movements suggests growing institutional interest
  • Institutional interest signals: Strong buying pressure in the options market

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting Cue Biopharma's progress in developing novel immunotherapies and collaborations.

Sentiment Assessment: Aggregate sentiment is POSITIVE (7/10), reflecting the optimism surrounding the company's advancements.

Catalyst Identification: Upcoming catalysts include potential earnings announcements and regulatory updates related to the company's product pipeline.

Market Narrative: The positive news headlines have aligned with the technical signals, driving the bullish momentum. However, investors should be cautious of potential risks and volatility in the biotech industry.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta 2.90), reflecting the company's high volatility and potential for significant price movements.

Volatility Regime: Current vs historical volatility levels: Higher than average, with a volatility rank of 718.8%.

Options Market Signals: IV rank: Medium (43.1%), suggesting historically medium volatility Put/call ratios: Neutral (0.86) Unusual activity: Strong buying pressure in the options market

Downside Protection: Support levels: $29.68 (SMA 20), $24.50 (lower Bollinger Band)

Market Context & Positioning

Sector Performance: Cue Biopharma is a biotech company, which has been performing strongly in recent months.

Institutional Activity: Volume patterns suggest growing institutional interest and buying pressure.

Correlation Analysis: The stock moves relatively independently of the market (R-squared 0.19), reflecting its high volatility and potential for significant price movements.

Relative Valuation: Position within trading range, with a recent breakout above the upper Bollinger Band

Key Levels & Action Items

Critical Price Levels:

  • Resistance: $34.86
  • Support: $29.68 (SMA 20)

Breakout/Breakdown Levels:

  • Breakout level: $36.41 (upper Bollinger Band)
  • Breakdown level: $26.51 (lower Bollinger Band)

Time-Sensitive Catalysts: Earnings announcements and regulatory updates related to the company's product pipeline.

Risk Management: Stop-loss levels at $28.50, with position sizing considerations based on volatility and recent price movements.

Generated
Earnings History
4 of 4 under expected move
Avg Expected Move
96.44%
Avg Actual Move
6.03%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-14 Pre-Market 50.34% 1.01% 0.02x Within
2025-03-31 After-Close 200.88% 15.11% 0.08x Within
2025-08-12 Pre-Market 21.05% 4.98% 0.24x Within
2025-11-12 Pre-Market 113.47% 3.00% 0.03x Within
Options Activity
IV Rank (30D)
71.18
IV Rank (7D)
71.18
Avg IV
1175.6%
Straddle (30D)
$4.15
Straddle (7D)
$4.15
P/C Volume
0.47
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.70
Correlation (SPY)
17.6%
R²
0.03
Ann. Volatility
198.8%
SPY Volatility
13.0%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 3,627,377 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

52 filers4,677,948 shares$53.17M value128.96% of float
# Filer Shares Value % of Total % of Float Period
1 Bleichroeder LP 370,682 $11.70M 22.00% 10.22% 2026-06-30
2 DRIEHAUS CAPITAL MANAGEMENT LLC 292,144 $9.22M 17.34% 8.05% 2026-06-30
3 VANGUARD CAPITAL MANAGEMENT LLC 161,700 $5.10M 9.60% 4.46% 2026-06-30
4 Ikarian Capital, LLC 104,364 $3.29M 6.20% 2.88% 2026-06-30
5 Tetragon Partners GP Ltd 93,819 $2.96M 5.57% 2.59% 2026-06-30
6 STEMPOINT CAPITAL LP 66,995 $2.11M 3.98% 1.85% 2026-06-30
7 BlackRock, Inc. Custodian 57,807 $1.82M 3.43% 1.59% 2026-06-30
8 ADAR1 Capital Management, LLC 55,193 $1.74M 3.28% 1.52% 2026-06-30
9 Lion Point Capital, LP 52,928 $1.67M 3.14% 1.46% 2026-06-30
10 Squadron Capital Management LLC 50,000 $1.58M 2.97% 1.38% 2026-06-30
11 DIADEMA PARTNERS LP 48,369 $1.53M 2.87% 1.33% 2026-06-30
12 GEODE CAPITAL MANAGEMENT, LLC Custodian 47,824 $1.51M 2.84% 1.32% 2026-06-30
13 BOOTHBAY FUND MANAGEMENT, LLC 31,459 $992.85K 1.87% 0.87% 2026-06-30
14 VANGUARD GROUP INC Custodian 3,014,034 $919.28K 1.73% 83.09% 2025-12-31
15 UBS Group AG Custodian 26,700 $842.65K 1.58% 0.74% 2026-06-30
16 CITADEL ADVISORS LLC Custodian 25,633 $808.98K 1.52% 0.71% 2026-06-30
17 VANGUARD FIDUCIARY TRUST CO 24,476 $772.46K 1.45% 0.67% 2026-06-30
18 Texas Capital Bank Wealth Management Services Inc 22,881 $722.12K 1.36% 0.63% 2026-06-30
19 RENAISSANCE TECHNOLOGIES LLC 14,689 $463.58K 0.87% 0.40% 2026-06-30
20 STATE STREET CORP (STT, STT-PG) 14,176 $447.39K 0.84% 0.39% 2026-06-30
21 Persistent Asset Partners Ltd 12,332 $389.20K 0.73% 0.34% 2026-06-30
22 Robertson Stephens Wealth Management, LLC 11,133 $351.36K 0.66% 0.31% 2026-06-30
23 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 11,003 $347.25K 0.65% 0.30% 2026-06-30
24 Seven Fleet Capital Management LP 10,702 $337.75K 0.64% 0.29% 2026-06-30
25 NORTHERN TRUST CORP Custodian 9,122 $287.89K 0.54% 0.25% 2026-06-30
3 filers$113.81K notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $78.90K 69.33% 2026-06-30
2 Belvedere Trading LLC $34.90K 30.67% 2026-06-30
3 DIADEMA PARTNERS LP $6 <0.01% 2026-06-30
1 filers$315.60K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $315.60K 100.00% 2026-06-30
Insider Activity
Latest: 2026-08-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-28 Pamela Garzone Director Award (A) +18,900 — EDGAR
2026-08-28 Pasha Sarraf Director Award (A) +18,400 — EDGAR
2026-08-17 Michael Vincent Meluzio VP, Prin. Accounting Officer Mixed +8,019 $30.09 -$169.3K EDGAR
2026-08-17 Sumita Ray Chief Legal Compliance Officer Mixed +9,367 $30.09 -$265.6K EDGAR
2026-08-14 Shao-Lee Lin Chief Executive Officer Mixed +50,921 $27.58 -$1.61M EDGAR
2026-08-03 James M Ahlers Chief Financial Officer Award (A) +25,500 — EDGAR
2026-07-30 Shao-Lee Lin Chief Executive Officer Grant (A) +136,359 RSU — EDGAR
2026-07-15 Dominique Christian Borie Chief Medical Officer Award (A) +31,500 — EDGAR
2026-07-10 Pamela Garzone Director Award (A) +21,800 — EDGAR
2026-07-10 Daniel A. Camardo Director Award (A) +21,800 — EDGAR
2026-07-10 Sumita Ray Chief Legal Compliance Officer Award (A) +54,589 — EDGAR
2026-07-10 Shao-Lee Lin Chief Executive Officer Award (A) +327,537 — EDGAR
2026-07-10 Pasha Sarraf Director Award (A) +21,800 — EDGAR
2026-07-10 Michael Vincent Meluzio VP, Prin. Accounting Officer Award (A) +40,942 — EDGAR
2026-07-10 Viola Mong Meehan Director Award (A) +21,800 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
20 insiders · @ $31.70
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Shao-Lee Lin Chief Executive Officer 716,455 $22.71M -$1.61M 5 2026-08-14
2 Sumita Ray Chief Legal Compliance Officer 124,991 $3.96M -$265.6K 2 2026-08-17
3 Michael Vincent Meluzio VP, Prin. Accounting Officer 53,070 $1.68M -$169.3K 2 2026-08-17
4 Aaron G.L. Fletcher Director 36,833 $1.17M $4.48M 9 2023-01-05
5 Dominique Christian Borie Chief Medical Officer 31,500 $998.5K $0 1 2026-07-15
6 Pasha Sarraf Director 29,195 $925.5K $99.7K 5 2026-08-28
7 CHRISTOPHER A MARLETT Director 25,617 $812.1K -$963.5K 16 2020-01-06
8 James M Ahlers Chief Financial Officer 25,500 $808.4K $0 1 2026-08-03
9 Cameron Gray Director 24,620 $780.5K $151.5K 8 2022-06-16
10 Viola Mong Meehan Director 21,800 $691.1K $0 2 2026-07-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-08-14
Last 30d: 0 filings  ·  Last 90d: 2 filings · $1.3M notice value · 2 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Shao-Lee Lin (1, $1.1M) · Sumita Ray (1, $266K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-14 Shao-Lee Lin Officer, Director 40,000 $1.08M 2026-08-12 Maxim Group LLC — EDGAR
2026-08-13 Sumita Ray Officer, CORPORATE SECRETARY 8,829 $266.1K 2026-08-13 Maxim Group LLC — EDGAR
2025-12-29 MATTEO GIACOMO LEVISETTI Officer 7,230 $1.9K 2025-12-29 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio99.7
P/S Ratio6.1
EV/EBITDA-2.2
TTM Revenue$0.0B
TTM Net Income$-0.0B
TTM EPS$-4.98
ROE-7104.2%
Debt/Equity0.42